Key result
Incretin-based therapies emerge as effective treatments for obesity-related HFpEF.
Why the study?
The increasing prevalence of obesity has led to complex interactions with heart failure, necessitating updated understanding of mechanisms, diagnostics, and treatments.
Obesity significantly complicates the diagnosis and management of heart failure, but emerging incretin-based therapies offer promising benefits, particularly in HFpEF, though diagnostic tools like NT-proBNP and echocardiography require careful interpretation in this population.
May warrant cautious diagnostic interpretation in obese HF patients; supports exploration of incretin therapies in HFpEF but requires prospective validation.
The prevalence of obesity among the general population has resulted in significant overlap and complex interactions with heart failure. This review aims to describe recent changes to the definition of obesity and explore direct and indirect mechanistic links between obesity and heart failure. Diagnostic challenges presented by obesity regarding echocardiography and B-type natriuretic peptide are also explored. Treatment options and the evidence base for addressing obesity in heart failure are examined across both heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Finally, the safety profile of new incretin-based therapies is examined.
No takes yet. Share an insight, caveat, or question.
Pathan et al. (2026) conducted a review in Heart failure and obesity. Incretin-based therapies and weight management was evaluated. Obesity contributes to heart failure pathophysiology and complicates diagnosis, but incretin-based therapies have emerged as effective treatments for obesity-related HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: